Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity

被引:110
作者
Khojasteh, Siamak Cyrus [1 ]
Prabhu, Saileta [1 ]
Kenny, Jane R. [1 ]
Halladay, Jason S. [1 ]
Lu, Anthony Y. H. [2 ]
机构
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Rutgers State Univ, Dept Biol Chem, Ernest Mario Coll Pharm, Piscataway, NJ 08854 USA
关键词
IN-VITRO INHIBITION; MECHANISM-BASED INACTIVATION; SEROTONIN REUPTAKE INHIBITORS; PHENACETIN O-DEETHYLATION; TIME-DEPENDENT INHIBITION; DRUG-DRUG INTERACTIONS; POTENT INHIBITOR; N-DEMETHYLATION; MESSENGER-RNA; TRIAZOLAM BIOTRANSFORMATION;
D O I
10.1007/s13318-011-0024-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The majority of marketed small-molecule drugs undergo metabolism by hepatic Cytochrome P450 (CYP) enzymes (Rendic 2002). Since these enzymes metabolize a structurally diverse number of drugs, metabolism-based drug-drug interactions (DDIs) can potentially occur when multiple drugs are coadministered to patients. Thus, a careful in vitro assessment of the contribution of various CYP isoforms to the total metabolism is important for predicting whether such DDIs might take place. One method of CYP phenotyping involves the use of potent and selective chemical inhibitors in human liver microsomal incubations in the presence of a test compound. The selectivity of such inhibitors plays a critical role in deciphering the involvement of specific CYP isoforms. Here, we review published data on the potency and selectivity of chemical inhibitors of the major human hepatic CYP isoforms. The most selective inhibitors available are furafylline (in co-incubation and pre-incubation conditions) for CYP1A2, 2-phenyl-2-(1-piperidinyl)propane (PPP) for CYP2B6, montelukast for CYP2C8, sulfaphenazole for CYP2C9, (-)-N-3-benzyl-phenobarbital for CYP2C19 and quinidine for CYP2D6. As for CYP2A6, tranylcypromine is the most widely used inhibitor, but on the basis of initial studies, either 3-(pyridin-3-yl)-1H-pyrazol-5-yl)methanamine (PPM) and 3-(2-methyl-1H-imidazol-1-yl)pyridine (MIP) can replace tranylcypromine as the most selective CYP2A6 inhibitor. For CYP3A4, ketoconazole is widely used in phenotyping studies, although azamulin is a far more selective CYP3A inhibitor. Most of the phenotyping studies do not include CYP2E1, mostly because of the limited number of new drug candidates that are metabolized by this enzyme. Among the inhibitors for this enzyme, 4-methylpyrazole appears to be selective.
引用
收藏
页码:1 / 16
页数:16
相关论文
共 192 条
  • [1] Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis
    Atkinson, A
    Kenny, JR
    Grime, K
    [J]. DRUG METABOLISM AND DISPOSITION, 2005, 33 (11) : 1637 - 1647
  • [2] Baldwin SJ, 1999, BRIT J CLIN PHARMACO, V48, P424
  • [3] KETOCONAZOLE AND SULFAPHENAZOLE AS THE RESPECTIVE SELECTIVE INHIBITORS OF P4503A AND 2C9
    BALDWIN, SJ
    BLOOMER, JC
    SMITH, GJ
    AYRTON, AD
    CLARKE, SE
    CHENERY, RJ
    [J]. XENOBIOTICA, 1995, 25 (03) : 261 - 270
  • [4] Baune B, 1999, DRUG METAB DISPOS, V27, P565
  • [5] Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man
    Becquemont, L
    Le Bot, MA
    Riche, C
    Funck-Brentano, C
    Jaillon, P
    Beaune, P
    [J]. PHARMACOGENETICS, 1998, 8 (02): : 101 - 108
  • [6] Evaluation of fluorescence- and mass spectrometry - Based CYP inhibition assays for use in drug discovery
    Bell, Leslie
    Bickford, Shari
    Nguyen, Phong Hung
    Wang, Jianling
    He, Timothy
    Zhang, Bailin
    Friche, Yannick
    Zimmerlin, Alfred
    Urban, Laszlo
    Bojanic, Dejan
    [J]. JOURNAL OF BIOMOLECULAR SCREENING, 2008, 13 (05) : 343 - 353
  • [7] The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
    Bjornsson, TD
    Callaghan, JT
    Einolf, HJ
    Fischer, V
    Gan, L
    Grimm, S
    Kao, J
    King, SP
    Miwa, G
    Ni, L
    Kumar, G
    McLeod, J
    Obach, RS
    Roberts, S
    Roe, A
    Shah, A
    Snikeris, F
    Sullivan, JT
    Tweedie, D
    Vega, JM
    Walsh, J
    Wrighton, SA
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) : 815 - 832
  • [8] CHARACTERIZATION OF THE CYTOCHROME-P450 ENZYMES INVOLVED IN THE IN-VITRO METABOLISM OF GRANISETRON
    BLOOMER, JC
    BALDWIN, SJ
    SMITH, GJ
    AYRTON, AD
    CLARKE, SE
    CHENERY, RJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (06) : 557 - 566
  • [9] FLUVOXAMINE IS A POTENT INHIBITOR OF CYTOCHROME-P4501A2
    BROSEN, K
    SKJELBO, E
    RASMUSSEN, BB
    POULSEN, HE
    LOFT, S
    [J]. BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) : 1211 - 1214
  • [10] Drug interactions of paclitaxel metabolism in human liver microsomes
    Bun, SS
    Ciccolini, J
    Bun, H
    Aubert, C
    Catalin, J
    [J]. JOURNAL OF CHEMOTHERAPY, 2003, 15 (03) : 266 - 274